Company: HURA
Filing Date: 2025-04-01
Form Type: 425
Source: 0001193125-25-069713
Chunk: 10

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-04-01
Form: 425
Chunk 10
---
URA’s lead innate immune agonist drug candidate, IFx-2.0, is designed to overcome primary resistance to
checkpoint inhibitors. TuHURA is preparing to initiate in the second quarter 2025, a single randomized placebo-controlled Phase 3 registration=directed trial of IFx-2.0 administered as an adjunctive therapy to
Keytruda (pembrolizumab) compared to Keytruda and placebo in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

In addition to its innate immune agonist candidates, following the anticipated closing of the previously announced proposed merger with Kineta, TuHURA
plans to advance its VISTA inhibiting antibody into a phase two trial in combination with a menin inhibitor in NPM1 mutated relapsed or refractory AML. Leveraging its discovery of the central role the delta opioid receptor plays in modulating the
immunosuppressive effects of myeloid derived suppressor cells (MDSCs) and tumor associated M2 polarized macrophages on the tumor microenvironment (TME), the Company is also developing non-tumor targeting ADCs
and APCs to convert the TME to an immunogenic phenotype, potentially overcoming acquired resistance to checkpoint inhibitors and cellular therapies.

For
more information, please visit and connect with TuHURA on , , and .

IMPORTANT ADDITIONAL INFORMATION

In connection with the
proposed acquisition by merger of Kineta, Inc. (“Kineta”) by TuHURA (the “Merger”), TuHURA filed with the U.S. Securities and Exchange Commission (the “SEC”) a registration statement on Form S-4, dated February 7, 2025 (the “Registration Statement”), which contains a preliminary joint proxy statement of Kineta and TuHURA and a preliminary prospectus of TuHURA (the “Joint Proxy
Statement/Prospectus”), and TuHURA and Kineta may file with the SEC other relevant documents regarding the Merger.Investors and securityholders of TuHURA and Kineta are urged to read the Joint Proxy Statement/Prospectus and such other materials carefully when they become available because they will contain important information about TuHURA, Kineta, and the proposed Merger. This press release is not a substitute for the definitive Joint Proxy Statement/Prospectus, when it becomes available, or any other documents that TuHURA may file with the SEC or send to securityholders in connection with the proposed Merger.

A definitive copy